Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NCNO -19.2%, CAL -15.7%, S -15.2%, SIG -15%, AEO -13.1%, AVAV -10.5%, KFY -8.7%, SNPS -8.2%, PVH -6.3%, CSIQ -6%, TD -3.2%, BMO -2.4%, GEF -2.2%, PDCO -1.6%, GMS -1.3%, BKE -1.3% (Nov comps)
Other news:
- AEYE -10.2% (prices secondary offering of up to 1,250,000 shares of its common stock to be sold by certain selling stockholders at $24.00 per share)
- MYO -6% (priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00/share)
- SMTC -5.1% ($400 mln stock offering)
- AS -5% (prices offering of 40.8 mln ordinary shares at $23.00 per share)
- MESO -4.8% (receives grant from FDA for Revascor Regenerative Medicine Advanced Therapy Designation in children with congenital heart disease)
- CGON -2.5% (Groundbreaking cretostimogene grenadenorepvec monotherapy data demonstrates sustained, durable complete responses in high-risk BCG-unresponsive non-muscle invasive bladder cancer)
- NKTX -2.2% (Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2)
- GAU -1.5% (terminates its gold purchase and sale agreement with Red Kite)
- FTDR -1.5% (launches $1.47 bln credit facility to fund acquisition of 2-10 Home Buyers Warranty and to refinance the company's existing credit facilities)
- COFS -1.3% (increases dividend)
- PAC -1% (reports Nov traffic)
- CRVS -1% (announces publication of biochemistry and preclinical data)